Wilmer Cutler Pickering Hale and Dorr represented Agios Pharmaceuticals, Inc. in the deal. Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Apellis Pharmaceuticals, Inc. on the deal, while Mintz, Levin, Cohn, Ferris, Glovsky, and Popeo and Proskauer Eose advised Sixth...
You must be a Standard 1 Year member to access this content.
Wilmer Cutler Pickering Hale and Dorr advised Karyopharm Therapeutics Inc. on the transactions. Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies,...
You must be a Standard 1 Year member to access this content.
Fenwick & West, Goodwin Procter and Maiwald represented Royalty Pharma in the transaction, Wilmer Cutler Pickering Hale and Dorr represented PTC Therapeutics. Royalty Pharma plc (Nasdaq:...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Wonder Group in the transaction, and Wilmer Cutler Pickering Hale and Dorr represented Blue Apron Holdings. Wonder Group (“Wonder”) announced that it has...
You must be a Standard 1 Year member to access this content.
WilmerHale represented Blue Apron in the transaction. Blue Apron (NYSE: APRN), an American ingredient-and-recipe meal kit company, announced the signing and closing of a transaction with...
You must be a Standard 1 Year member to access this content.
